Of these, CDC20, a regulatory protein involves in multi-cell cycle checkpoints was identified as a novel target molecule for CCA treatment and dinaciclib, a pan CDK inhibitor, was suggested as a compatible drug for CDC20. This evidence concerns the gene CDC20 and cholangiocarcinoma.